The primary goals of my research are to: 1) expand our understanding of the role of genetic variation in mitochondrial DNA (mtDNA) in outcomes of HIV infection and treatments; and 2) to characterize relevant biomarkers of adverse outcomes in treated HIV-infected persons. This work includes collaborations with the AIDS Clinical Trials Group (ACTG), the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) group, and multi-disciplinary teams of investigators including clinical pharmacologists, biostatisticians, mitochondrial geneticists, and computational biologists/geneticists. My projects bridge epidemiology-outcomes and clinical-translational research domains.
| Todd Hulgan [Email] Medicine, Infectious Diseases |
|
| Location |
South Africa; Thailand; Nashville, TN, USA; Multi-site US and global consortia |
| Contacts | N/A |
| Program Type |
Research |
| Funding Type |
N/A |
| Region |
Africa, Asia, North America |
| Global Health Topics |
Epidemiology, HIV/AIDS, Infectious diseases |
| Eligibility |
Graduate students (non-clinical); Medical students (MD); Post-doctoral students, residents, or trainees |
| Program Length |
Flexible, depending on the individuals interests and needs |
| VU Affiliation |
The program is affiliated with Vanderbilt. |
| Language(s) |
The program does not have a language requirement. |